Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aliskiren - Noden Pharma

Drug Profile

Aliskiren - Noden Pharma

Alternative Names: Aliskiren fumarate; Aliskiren hemi-fumarate; CGP 60536B; Enviage; Rasilez; Rasilles; Riprazo; SPP 100; SPP 100B; Sprimeo; Tekturna

Latest Information Update: 10 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Ohio State University
  • Class Amides; Antihypertensives; Fumarates; Small molecules
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Phase III Chronic heart failure
  • Discontinued Acute heart failure; Atherosclerosis; Diabetic macular oedema; Diabetic nephropathies; Kidney disorders; Myocardial infarction

Most Recent Events

  • 10 Jun 2019 PDL BIOPHARMA has patent protection for aliskiren in USA
  • 24 Jun 2018 Biomarkers information updated
  • 15 Nov 2017 Registered for Hypertension (In adolescents, In children) in USA (PO,pellets)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top